Eli Lilly puts faith in drug pipeline

Back to TopCommentsE-mailPrintBookmark and Share
Year In Review

Eli Lilly and Co. started to tip over its massive “patent cliff” this year, yet announced little publicly that will significantly soften its inevitable sales plunge.

On Nov. 15, generic versions of Lilly’s cancer drug Gemzar hit the market in the United States—the first of five blockbuster drugs that will lose patent protection in the United States or Europe over the next five years. Those losses will wipe out half the Indianapolis-based company’s $22 billion in annual revenue. And the picture got even worse this summer, when a court struck down the U.S. patent on Lilly’s drug Strattera.

The drugmaker has 68 experimental drugs in human testing right now, and it hopes to launch two of them per year, beginning in 2013, to revive its sales. But Lilly’s labs have produced that kind of performance only three times in the past 60 years.

Given those long odds—and Lilly’s recent struggles to win market approval for new products—most investors are cool on the stock. Lilly’s share price has been flat for two years, buoyed mainly by its rich dividend.

Lilly did win market approval late this year for a new underarm testosterone treatment it licensed from an Australian firm. But Lilly also suffered more than two years of further delays this year on Bydureon, its once-weekly diabetes medicine. And Lilly’s biggest pipeline hope—an experimental Alzheimer’s drug—failed miserably in a Phase 3 clinical trial, actually making the condition worse for patients.

Analysts have demanded to know what else Lilly plans to do to shore up its revenue and profits before its biggest drug, the antipsychotic Zyprexa, loses patent protection in November 2011 and more than $4 billion of sales evaporate.

Lilly’s answer has been consistent: no big merger, but instead efforts to grow sales in international markets and animal health and diagnostics, while it waits for its pipeline to deliver. At the same time, Lilly is slashing expenses by cutting jobs: It has eliminated more than 2,700 jobs on a path to 5,500 positions by the end of 2011.

“Our fundamental strategy remains intact,” Lilly CEO John Lechleiter said. “Nothwithstanding the setbacks, we’re confident we can execute on that strategy.”•


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ
  1. Only half a million TV Viewers? And thats an increase? I knew Indycar was struggling but I didn't know it was that bad. Hell, if NASCAR hits 5 Million viewers everyone starts freaking out saying its going down hill. It has a long way to before Indycar even hits NASCAR's bad days.

  2. IU has been talking that line for years with no real progress even with the last Dean, Dr. Brater. Why will an outsider, Dr. Hess, make a difference? With no proof of additional resources (cash in the bank), and a concrete plan to move an academic model that has been outdated for decades with a faculty complacent with tenure and inertia, I can count on IU to remain the same during the tenure of Dr. Hess. One ought to look to Purdue and Notre Dame for change and innovation. It is just too bad that both of those schools do not have their own medical school. Competition might wake up IU. My guess is, that even with those additions to our State, IU will remain in its own little world squandering our State's tax dollars. Why would any donor want to contribute to IU with its track record? What is its strategy to deal with the physician shortage for our State? New leadership will not be enough for us to expect any change.

  3. How do you think the Bridges got approved? I spent a couple days researching PAC's and individual contributions to some city council members during that time. My printouts were inches thick on the two I concentrated on. Finally gave up. Was disgusted with all the donations, and who they were from. Would have taken me days and days to compile a complete list. Tried to give it to the Star reporter, but he thought it was all just fine. (and apparently he was treated well himself) He ended up being laid off or fired though. And then of course, there was land donated to the dad's club, or city, as a partial payoff. All done in the shining example of "charity." No, none of these contributions are a coincidence.

  4. I agree what kind of help or if any will be there for Dr. Ley's patients. I was a patient myself.

  5. What about the hundreds of patients who sought this doctor for the right reasons, to quit drugs. what option do these patients now have, experience horrible withdrawl or return to heroin?? those are the choices. what about the children of these former addicts who's parent(s) WILL not b able to maintain their job, for @ least 2 weeks.. There needs to b an emergency clinic opened for these patients.